TA
IBRX icon

TCG Advisors’s ImmunityBio IBRX Stock Holding History

TCG Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10
Closed – – 511
2019
Q1 		$0 Buy
+10
New +$13 ﹤0.01% 494

Other funds holding IBRX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCG Advisors's IBRX Position: Q2 2019 in Review

TCG Advisors sold out of ImmunityBio (IBRX) in Q2 2019, closing a stake of 10 shares.

TCG Advisors first reported a position in IBRX in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 47 funds tracked by Wall St. Rank hold IBRX as of Q2 2019.

  • TCG Advisors reported no remaining ImmunityBio position as of Q2 2019 after selling out during the quarter.
  • TCG Advisors sold 10 ImmunityBio shares in Q2 2019.
  • TCG Advisors first reported a position in ImmunityBio in Q1 2019 and held it in 1 quarter.
  • TCG Advisors's ImmunityBio position peaked at $0 in Q1 2019.
  • 47 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2019.

Based on TCG Advisors's 13F filing for Q2 2019, filed 13 Aug 2019.